This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (21)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Robert N. Johnson, MD; Karl R. Olsen, MD; Eleut Hernandez

Arch Ophthalmol. 1989;107(6):891-894.

Abstract
• Intraocular recombinant DNA human tissue-type plasminogen activator (tPA) can promote rapid resolution of intraocular fibrin clots and hyphema. The efficacy of intravitreal tPA in promoting the shortterm clearance of vitreous hemorrhage was investigated. Five treatment groups with experimentally induced vitreous hemorrhage were studied. The extent of the vitreous hemorrhage was graded based on the visibility of retinal details in each quadrant. Two weeks following intravitreal tPA injection (50 000 IU), the nonvitrectomized group and gas vitrectomy groups, each of which received a single tPA injection, showed a statistically significant reduction of the vitreous hemorrhage, although this was thought to represent only a modest clinical effect. Tractional retinal detachments were noted to develop more frequently in tPA-treated eyes as compared with controls.

Author Affiliations
From the Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami School of Medicine. Dr Johnson was a Heed-Knapp Fellow, 1987 to 1988.

Footnotes
Accepted for publication Nov 23, 1988.

Presented in part at the Annual Meeting of the Association for Research in Vision and Ophthalmology, Sarasota, Fla, May 6, 1988, and at the 24th Bascom Palmer Eye Institute Residents' Day, Miami, June 10, 1988.

Reprint requests to Bascom Palmer Eye Institute, PO Box 016880, Miami, FL 33101 (Dr Olsen).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Treatment of recent onset central retinal vein occlusion with intravitreal tissue plasminogen activator: a pilot study
Glacet-Bernard et al.
Br J Ophthalmol 2000;84:609-613.
ABSTRACT | FULL TEXT  

Plasminogen in proliferative vitreoretinal disorders
Esser et al.
Br J Ophthalmol 1997;81:590-594.
ABSTRACT | FULL TEXT  

Retinal Toxicity of Recombinant Tissue Plasminogen Activator in the Rabbit
Johnson et al.
Arch Ophthalmol 1990;108:259-263.
ABSTRACT  

Rebleeding in Experimental Traumatic Hyphema Treated With Intraocular Tissue Plasminogen Activator
Williams et al.
Arch Ophthalmol 1990;108:264-266.
ABSTRACT